Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: Physicochemical characterization and in vivo investigation

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1819-1830

  Yousaf, Abid Mehmood ^a   Kim, Dong Wuk ^a   Oh, Yu Kyoung ^b   Yong, Chul Soon ^c   Kim, Jong Oh ^c   Choi, Han Gon ^a  

^a Hanyang University   (South Korea)

^b Seoul National University   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

Ameliorated oral bioavailability; Crystallinity; Gelatin nanocapsules; Hydrophilic polymeric matrix

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN NANOCORPUSCLE; DODECYL SULFATE SODIUM; FENOFIBRATE; GELATIN NANOCAPSULE; NANOPARTICLE; POLYVINYLPYRROLIDONE NANOSPHERE; UNCLASSIFIED DRUG; WATER; NANOCAPSULE; POLYMER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PHYSICAL CHEMISTRY; PHYSICAL PHENOMENA; PLASMA CONCENTRATION-TIME CURVE; POWDER; RAT; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SOLVENT EVAPORATION; SPRAY DRYING; WEIGHT; WETTABILITY; X RAY POWDER DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PROCEDURES;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; FENOFIBRATE; NANOCAPSULES; NANOTECHNOLOGY; POLYMERS; RATS;

EID: 84924300016     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S78895     Document Type: Article

References (70)

1. Guay D. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother. 1999;33(10):1083-1103.
2. Genest JJ, Nguyen N-H, Theroux P, Davignon J, Cohn JS. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol. 2000;35(1):164-172.
3. Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis. 1994;110(suppl(0)):S45-S48.
4. Ming-Thau S, Ching-Min Y, Sokoloski TD. Characterization and dissolution of fenofibrate solid dispersion systems. Int J Pharm. 1994;103(2):137-146.
5. Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: where do we go from here? Pharm Technol. 2001;25(7):68-77.
6. Badens E, Majerik V, Horváth G, et al. Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. Int J Pharm. 2009;377(1-2):25-34.
7. Cutler L, Howes C, Deeks NJ, Buck TL, Jeffrey P. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J Pharm Sci. 2006;95(9):1944-1953.
8. Yoshihashi Y, Iijima H, Yonemochi E, Terada K. Estimation of physical stability of amorphous solid dispersion using differential scanning calorimetry. J Therm Anal Calorim. 2006;85(3):689-692.
9. Goddeeris C, Coacci J, Van den Mooter G. Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds. Eur J Pharm Biopharm. 2007;66(2):173-181.
10. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47-60.
11. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes: part I: micronization of neat particles. Int J Pharm. 2005;288(1):3-10.
12. Jia Z, Lin P, Xiang Y, et al. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Eur J Pharm Biopharm. 2011;79(1):126-134.
13. Xing F, Cheng G, Yi K, Ma L. Nanoencapsulation of capsaicin by complex coacervation of gelatin, acacia, and tannins. J Appl Polym Sci. 2005;96(6):2225-2229.
14. Mora-Huertas C, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1):113-142.
15. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8-21.
16. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1):1-20.
17. Heng D, Cutler DJ, Chan H-K, Yun J, Raper JA. What is a suitable dissolution method for drug nanoparticles? Pharm Res. 2008;25(7):1696-1701.
18. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26(5):1025-1058.
19. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24(12):1113-1128.
20. Broadhead J, Edmond Rouan S, Rhodes C. The spray drying of pharmaceuticals. Drug Dev Ind Pharm. 1992;18(11-12):1169-1206.
21. Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci. 2005;26(2):219-230.
22. Joe JH, Lee WM, Park YJ, et al. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm. 2010;395(1-2):161-166.
23. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Expert Opin Drug Deliv. 2010;7(6):705-719.
24. Van Drooge D, Hinrichs W, Visser M, Frijlink H. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nanometer scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int J Pharm. 2006;310(1):220-229.
25. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-1302.
26. Jizomoto H, Kanaoka E, Sugita K, Hirano K. Gelatin-acacia microcapsules for trapping micro-oil droplets containing lipophilic drugs and ready disintegration in the gastrointestinal tract. Pharm Res. 1993;10(8):1115-1122.
27. Báez J, Olsen D, Polarek J. Recombinant microbial systems for the production of human collagen and gelatin. Appl Microbiol Biotechnol. 2005;69(3):245-252.
28. Piao MG, Yang CW, Li DX, et al. Preparation and in vivo evaluation of piroxicam-loaded gelatin microcapsule by spray drying technique. Biol Pharm Bull. 2008;31(6):1284-1287.
29. Menting L, Hoogstad B, Thijssen H. Diffusion coefficients of water and organic volatiles in carbohydrate-water systems. Int J Food Sci Technol. 1970;5(2):111-126.
30. Thijssen HAC. Flavour retention in drying preconcentrated food liquids. J Appl Chem Biotechnol. 1971;21(12):372-377.
31. Li DX, Yan YD, Oh DH, et al. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer. Drug Deliv. 2010;17(5):322-329.
32. Mehmood Yousaf A, Wuk Kim D, Choi H-G, Oh E. Validation of a highly sensitive RP-HPLC method for quantification of fenofibrate in pure and pharmaceutical dosage forms. Curr Pharm Anal. 2014;10(2):97-104.
33. Stamm A, Seth P, inventor; Labaratoires Fournier, assignee. Fenofibrate pharmaceutical composition having high bioavailabilty and method for preparing it. Google patents US 6277405.2001. Available from: http://www.google.com/patents/US6277405
34. Shah VP, Noory A, Noory C, et al. In vitro dissolution of sparingly water-soluble drug dosage forms. Int J Pharm. 1995;125(1):99-106.
35. Sanganwar GP, Gupta RB. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm. 2008;360(1-2):213-218.
36. Windbergs M, Strachan CJ, Kleinebudde P. Understanding the solid-state behaviour of triglyceride solid lipid extrudates and its influence on dissolution. Eur J Pharm Biopharm. 2009;71(1):80-87.
37. Oh DH, Park Y-J, Kang JH, Yong CS, Choi H-G. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change. Drug Deliv. 2011;18(1):46-53.
38. Society of Toxicology. Guiding Principles in the Use of Animals in Toxicology. Reston, VA: Society of Toxicology; 2008.
39. Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm. 2009;35(7):827-833.
40. Straka RJ, Burkhardt RT, Fisher JE. Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum. Ther Drug Monit. 2007;29(2):197-202.
41. Streel B, Hubert P, Ceccato A. Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography. J Chromatogr B Biomed Sci Appl. 2000;742(2):391-400.
42. Tang N, Lai J, Chen Y, Lu Y, Wu W. Fenofibrate solid dispersion pellets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogs. J China Pharm Sci. 2009;18(2):156-161.
43. Dave RH, Patel HH, Donahue E, Patel AD. To evaluate the change in release from solid dispersion using sodium lauryl sulfate and model drug sulfathiazole. Drug Dev Ind Pharm. 2013;39(10):1562-1572.
44. Giri TK, Badwaik H, Alexander A, Tripathi DK. Solubility enhancement of ibuprofen in the presence of hydrophilic polymer and surfactant. Int J Appl Biol Pharm Tech. 2010;1(2):793-800.
45. Kim MS, Kim JS, Park HJ, Cho WK, Cha K-H, Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997.
46. Leane MM, Sinclair W, Qian F, et al. Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant. Pharm Dev Technol. 2013;18(2):359-366.
47. Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel. Int J Pharm. 2011;420(2):244-250.
48. Hancock B, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397-404.
49. Müller BW, Brauns U. Solubilization of drugs by modified β-cyclodextrins. Int J Pharm. 1985;26(1-2):77-88.
50. Pitha J, Pitha J. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J Pharm Sci. 1985;74(9):987-990.
51. Antoniadou-Vyza E, Buckton G, Michaleas SG, Loukas YL, Efentakis M. The formation of an inclusion complex of methocarbamol with hydroxypropyl-β-cyclodextrin: the effect on chemical stability, solubility and dissolution rate. Int J Pharm. 1997;158(2):233-239.
52. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86(2):147-162.
53. Miro A, Quaglia F, Giannini L, Cappello B, Immacolata La Rotonda M. Drug/cyclodextrin solid systems in the design of hydrophilic matrices: a strategy to modulate drug delivery rate. Curr Drug Deliv. 2006;3(4):373-378.
54. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm. 2004;272(1-2):1-10.
55. Van Den Bulcke AI, Bogdanov B, De Rooze N, Schacht EH, Cornelissen M, Berghmans H. Structural and rheological properties of methacrylamide modified gelatin hydrogels. Biomacromolecules. 2000;1(1):31-38.
56. Djabourov M, Papon P. Influence of thermal treatments on the structure and stability of gelatin gels. Polymer. 1983;24(5):537-542.
57. Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131-144.
58. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3-4):278-287.
59. Taylor L, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691-1698.
60. Doherty C, York P. Accelerated stability of an X-Ray amorphous frusemide-polyvinylpyrrolidone solid dispersion. Drug Dev Ind Pharm. 1989;15(12):1969-1987.
61. Rege BD, Yu LX, Hussain AS, Polli JE. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci. 2001;90(11):1776-1786.
62. Briseid G, Briseid K, Kirkevold K. Increased intestinal absorption in the rat caused by sodium lauryl sulphate, and its possible relation to the cAMP system. Naunyn Schmiedebergs Arch Pharmacol. 1976;292(2):137-144.
63. Miller JM, Beig A, Krieg BJ, et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8(5):1848-1856.
64. Dai W-G, Dong LC, Song Y-Q. Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int J Pharm. 2007;342(1):201-207.
65. Mura P, Cirri M, Faucci M, Ginès-Dorado J, Bettinetti G. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal. 2002;30(2):227-237.
66. Yonemochi E, Kitahara S, Maeda S, Yamamura S, Oguchi T, Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur J Pharm Sci. 1999;7(4):331-338.
67. Kubo H, Mizobe M. Improvement of dissolution rate and oral bioavailability of a sparingly water-soluble drug, (+/-)-5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl] methyl]-2,4-thiazolidinedione, in co-ground mixture with d-mannitol. Biol Pharm Bull. 1997;20:460-463.
68. Purvis T, Vaughn JM, Rogers TL, et al. Cryogenic liquids, nanoparticles, and microencapsulation. Int J Pharm. 2006;324(1):43-50.
69. Chow AH, Hsia CK, Gordon JD, Young JW, Vargha-Butler EI. Assessment of wettability and its relationship to the intrinsic dissolution rate of doped phenytoin crystals. Int J Pharm. 1995;126(1):21-28.
70. Kawashima Y, Saito M, Takenaka H. Improvement of solubility and dissolution rate of poorly water-soluble salicylic acid by a spray-drying technique. J Pharm Pharmacol. 1975;27(1):1-5.